{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-035953","form_type":"8-K","ticker":"ALDX","cik":"0001341235","company_name":"Aldeyra Therapeutics, Inc.","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.021577+00:00","generated_at":"2026-06-03T07:40:32.996496+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aldeyra R&D Day: reproxalap NDA resubmission H2 2024; positive preclinical data for ADX-246, ADX-629","bullets":["Reproxalap NDA resubmission expected H2 2024, pending Phase 3 dry eye chamber trial results and FDA discussions.","ADX-629 showed statistically significant improvement in EASI, itching, and POEM scores in Phase 2 atopic dermatitis trial.","ADX-246 reduced hepatic acetaldehyde, histopathology, and liver enzymes in preclinical alcoholic hepatitis model.","ADX-629 enhanced GLP-1-mediated weight and fat mass loss in a diet-induced obesity mouse model.","Next-generation RASP modulators ADX-248 and ADX-246 demonstrated broad activity in preclinical inflammation models."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-035953","json":"https://secwatch.observer/filing/0001213900-24-035953.json","markdown":"https://secwatch.observer/filing/0001213900-24-035953.md","text":"https://secwatch.observer/filing/0001213900-24-035953.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1341235/000121390024035953/0001213900-24-035953-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1341235/000121390024035953/ea0204620-8k_aldey.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T07:40:32.996496+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}